Skip to content

Study · Non-randomized trial · n = 26 · 1996

4 results

Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis.

Fredrikson S

Acta neurologica Scandinavica1 Jul 1996Cited by 26 (Europe PMC)

PMID8874590 (opens in a new tab)DOI10.1111/j.1600-0404.1996.tb00035.x (opens in a new tab)PepBankPUB-08874590
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin significantly decreased voidings during the 6-h period after administration.

    In plain wordsIn patients with multiple sclerosis, desmopressin reduced voidings during the 6-h period after administration.

    Peptide
    Desmopressin
    Outcome
    DecreaseVoiding frequency
    Study

    n = 26

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    There was a significant decrease in the number of voidings during the 6-h period after intranasal intake of desmopressin.
    2 context sentences
    Summary · context
    In the present study, the effect of the synthetic vasopressin analogue, desmopressin, was evaluated on the voiding frequency in 26 patients with MS suffering from socially handicapping voidings and incontinence problems during daytime.
    Summary · context
    A two-week run-in observation period to establish normal voiding patterns was followed by a double-blind, placebo-controlled cross-over study with 20 micrograms intranasal desmopressin during daily activities.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis, side effects of intranasal desmopressin were well tolerated.

    In plain wordsIn patients with multiple sclerosis, desmopressin side effects were well tolerated.

    Peptide
    Desmopressin
    Outcome
    Not applicableSide effect tolerability
    Study

    n = 26

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Side effects were well tolerated and there was no hyponatremia or hypertension registered.
    2 context sentences
    Summary · context
    In the present study, the effect of the synthetic vasopressin analogue, desmopressin, was evaluated on the voiding frequency in 26 patients with MS suffering from socially handicapping voidings and incontinence problems during daytime.
    Summary · context
    A two-week run-in observation period to establish normal voiding patterns was followed by a double-blind, placebo-controlled cross-over study with 20 micrograms intranasal desmopressin during daily activities.
  3. 03HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis receiving desmopressin, no hyponatremia was registered.

    In plain wordsIn patients with multiple sclerosis receiving desmopressin, no low blood sodium was registered.

    Peptide
    Desmopressin
    Outcome
    Not applicableHyponatremia
    Study

    n = 26

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Side effects were well tolerated and there was no hyponatremia or hypertension registered.
    2 context sentences
    Summary · context
    In the present study, the effect of the synthetic vasopressin analogue, desmopressin, was evaluated on the voiding frequency in 26 patients with MS suffering from socially handicapping voidings and incontinence problems during daytime.
    Summary · context
    A two-week run-in observation period to establish normal voiding patterns was followed by a double-blind, placebo-controlled cross-over study with 20 micrograms intranasal desmopressin during daily activities.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis receiving desmopressin, no hypertension was registered.

    In plain wordsIn patients with multiple sclerosis receiving desmopressin, no high blood pressure was registered.

    Peptide
    Desmopressin
    Outcome
    Not applicableHypertension
    Study

    n = 26

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 micrograms · intranasalAs given in this study (human).

    Source sentences

    Summary
    Side effects were well tolerated and there was no hyponatremia or hypertension registered.
    2 context sentences
    Summary · context
    In the present study, the effect of the synthetic vasopressin analogue, desmopressin, was evaluated on the voiding frequency in 26 patients with MS suffering from socially handicapping voidings and incontinence problems during daytime.
    Summary · context
    A two-week run-in observation period to establish normal voiding patterns was followed by a double-blind, placebo-controlled cross-over study with 20 micrograms intranasal desmopressin during daily activities.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.